Pituitary adenylate cyclase activating peptides are endothelium-independent dilators of human and porcine coronary arteries.
The PACAPs have been shown to be potent vasodilators in different animal species. Data in humans are still lacking. Therefore we investigated the effects of PACAP 38, PACAP 27 and VIP on isolated human and porcine coronary arteries (HCA and PCA). Our data show, that the PACAPs are endothelium-independent vasorelaxants, which in HCA are slightly more potent than VIP. The N-terminal shortened peptides PACAP 6-38 and PACAP 6-27 also show relatively potent vasorelaxant effects, acting as partial agonists. Glibenclamide, a selective inhibitor of ATP-sensitive potassium channels, partially reverses the effects of the PACAPs, indicating an involvement of these channels in the mechanism of action.
Kästner
A
A
Humboldt-Universität zu Berlin, Universitätsklinikum Charitè, I. Medizinische Klinik, Germany.
Bruch
L
L
Will-Shahab
L
L
Modersohn
D
D
Baumann
G
G
D000818:Animals; D003331:Coronary Vessels / Q000166:cytology / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000502:physiology; D005905:Glyburide / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D009479:Neuropeptides / Q000494:pharmacology*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000378:metabolism; D013045:Species Specificity; D013552:Swine; D014665:Vasodilator Agents / Q000494:pharmacology*
C495401:ADCYAP1 protein, human; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D014665:Vasodilator Agents; D005905:Glyburide